Literature DB >> 1350643

Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation.

T Visakorpi1, O P Kallioniemi, A Heikkinen, T Koivula, J Isola.   

Abstract

BACKGROUND: Mutations in the p53 gene resulting in the accumulation of altered p53 proteins with prolonged half-life have been found in a large variety of human malignancies.
PURPOSE: We studied the significance of p53 protein accumulation in prostatic carcinoma.
METHODS: The material consisted of 137 paraffin-embedded, primary prostatic carcinomas. Accumulation of p53 protein was studied by immunohistochemical staining using a polyclonal p53-specific CM-1 antibody. Proliferation activity was determined by DNA flow cytometry and by immunohistochemical detection of proliferative cell nuclear antigen (PCNA) using a monoclonal PC10 antibody.
RESULTS: Eight (6%) of the tumors showed intense p53 staining in more than 20% of the tumor cells, 15 (11%) had only lower level immunoreactivity, and 114 (83%) showed no staining. High-level p53 accumulation was associated with high histologic grade (P less than .001), DNA aneuploidy (P less than .05), and high cell proliferation rate as defined by flow cytometric S-phase analysis (P less than .01) or PCNA expression (P less than .01). High-level p53 accumulation predicted short, progression-free interval (P less than .01) and poor survival (P less than .001), with about a 12-fold relative risk of death as compared with p53-negative cases. Low-level p53 accumulation had no prognostic significance.
CONCLUSIONS: Accumulation of p53 confers proliferative advantage for prostatic carcinoma cells and defines a small subgroup of highly malignant carcinomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350643     DOI: 10.1093/jnci/84.11.883

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  45 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.

Authors:  M Guan; Y Chen
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

Review 3.  Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters.

Authors:  C Bokemeyer; M A Kuczyk; J Serth; J T Hartmann; H J Schmoll; U Jonas; L Kanz
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

4.  Prognostic significance of Bcl-2 in clinically localized prostate cancer.

Authors:  L Bubendorf; G Sauter; H Moch; P Jordan; A Blöchlinger; T C Gasser; M J Mihatsch
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

Review 5.  Tumor suppressor genes in molecular medicine.

Authors:  F Hoppe-Seyler; K Butz
Journal:  Clin Investig       Date:  1994-08

6.  p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.

Authors:  B G Schneider; S G Hilsenbeck; C H Hensel; V Pekkel; C H Shelton; H A Rodríguez-Martínez; M E Gutiérrez-Díaz; D R Pulitzer; D C Allred
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Immunoreactivity of proliferating cell nuclear antigen in salivary gland tumours: an assessment of growth potential.

Authors:  L Yang; K Hashimura; C Qin; P Shrestha; S Sumitomo; M Mori
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 8.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer.

Authors:  H Moch; G Sauter; D Moore; M J Mihatsch; F Gudat; F Waldman
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas.

Authors:  M Ittmann; R Wieczorek; P Heller; A Dave; J Provet; J Krolewski
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.